Table 3.
Change from baseline to endpoint on secondary efficacy measures.
| Outcome measure | Baseline |
Change from baseline to endpoint |
||||
|---|---|---|---|---|---|---|
| Ziprasidone Mean (SD) |
Placebo Mean (SD) |
P-value | Ziprasidone Mean (SD) |
Placebo Mean (SD) |
P-value | |
| HAM-A | 22.5 (7.0) | 22.5 (8.5) | 1.0 | −11.8 (12.2) | −6.7 (10.8) | 0.27 |
| HAM-D | 19.0 (4.4) | 17.8 (5.4) | 0.51 | −9.8 (8.3) | −5.8 (7.6) | 0.21 |
| TOP-8 | 20.0 (5.8) | 18.7 (4.4) | 0.53 | −10.1 (8.2) | −7.4 (8.0) | 0.41 |
| CGI-S | 4.9 (0.9) | 4.5 (1.0) | 0.38 | −1.9 (1.9) | −1.5 (1.7) | 0.53 |
| CGI-I | 3.5 (0.6) | 3.4 (1.2) | 0.92 | −1.2 (1.3) | −0.7 (1.5) | 0.40 |
HAM-A: Hamilton Anxiety Scale; HAM-D: Hamilton Rating Scale for Depression; TOP-8: Treatment Outcome PTSD Scale; CGI-S: Clinical Global Impression-Severity; CGI-I: Clinical Global Impression-Improvement.
Note: As the CGI-I is not obtained at baseline (Visit 1), Visit 2 scores are reported for Baseline.
Endpoint scores on secondary efficacy measures were unavailable for four patients (2 in ziprasidone group and 2 in placebo group). Baseline CGI-S was unavailable for one patient in the ziprasidone group, and visit 2 CGI-I was unavailable for one patient in the placebo group.